NicOx Kicks Off Specialty Ophthalmics Transformation With Altacor Buy
This article was originally published in The Pink Sheet Daily
France's NicOx, aiming to transform into a specialty ophthalmology company after several late-stage disappointments, announced plans to acquire VC-backed U.K startup Altacor.
You may also be interested in...
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
Like many other big pharma companies, Novartis AG faces an imminent patent cliff, with blood pressure blockbuster Diovan (valsartan), among other products, due to lose patent protection soon.
Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
FDA tells NicOx it wants long-term studies on drug's cardiovascular and gastrointestinal safety, but no additional efficacy trials.